Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5180770 | 1.00 | KDM4E (0.34) | KDM4EGAASMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL4179681 | 0.84 | KDM4E (0.39) | KDM4EGAASMN1; SMN2 | |
| SCHEMBL4179685 | 0.84 | KDM4E (0.39) | KDM4EGAASMN1; SMN2 | |
| SCHEMBL5181396 | 0.83 | ALDH1A1 (0.37) | KDM4EGAASMN1; SMN2 | |
| SCHEMBL5181400 | 0.83 | ALDH1A1 (0.37) | KDM4EGAASMN1; SMN2 | |
| SCHEMBL5180028 | 0.77 | ALDH1A1 (0.34) | KDM4ESMN1; SMN2 | |
| SCHEMBL5180922 | 0.76 | CRHBP (0.34) | KDM4EGAASMN1; SMN2 | |
| SCHEMBL12123689 | 0.75 | HTT (0.37) | KDM4EGAASMN1; SMN2 | |
| SCHEMBL4184410 | 0.74 | PTGS1 (0.37) | KDM4EGAAPTGS1PTGS2 | |
| SCHEMBL6742388 | 0.68 | TSHR (0.40) | KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414440-B1 | N-PHENYLPYRROLE GUANIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR LIGANDS | ACTION PHARMA AS (DK) | 2007-01-10 | — | — | EP | claimed |
| US-20060148798-A1 | N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands | ACTION PHARMA A/S (DK) | 2006-07-06 | — | — | US | claimed |
| EP-1414440-B1 | N-PHENYLPYRROLE GUANIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR LIGANDS | ACTION PHARMA AS (DK) | 2007-01-10 | — | — | EP | disclosed |
| US-20060148798-A1 | N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands | ACTION PHARMA A/S (DK) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148798-A1 | N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands | MC1R, MC5R, MC3R | KDM4E 1441/4885GAA 3366/4885SMN1; SMN2 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.